OnCusp Therapeutics
PrivateLast Round
Series A
Jan 4, 2024
Total Funding Raised
$139M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
OnCusp Therapeutics is an oncology company that develops innovative, first-in-class cancer therapies by translating preclinical research into clinical treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OnCusp Therapeutics Comparables
Compare OnCusp Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Multitude Therapeutics | 85% | |
| Phrontline Biopharma | 81% | |
| Adcendo | 78% |
OnCusp Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 4, 2024 | ||||
| Seed | Aug 1, 2022 | ||||
| Seed | Apr 1, 2021 |
Key People
Founding team and executive leadership
OnCusp Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series A, Seed |
| F-Prime Capital | Series A |
| OrbiMed | Series A |
| Catalio Capital Management | Series A |
| Forge Life Science Partners | Series A |
| Novo Holdings | Series A |
| F-Prime Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 39% MoM, reaching 2.2K.
- Jun 23, 2025
Dimitry S.A. Nuyten appointed as the new Chief Medical Officer.
OnCusp Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OnCusp Therapeutics's valuation, stock price, and market status.
Is OnCusp a public or private company?
OnCusp is a private company.
What is the current stock price of OnCusp?
OnCusp is a private company with no public stock price. No recent secondary market data is available.
How much is OnCusp worth (valuation)?
Valuation information for OnCusp is not publicly available.
Can I buy OnCusp stock?
OnCusp shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was OnCusp's last funding round?
OnCusp's most recent funding round was Series A on January 4, 2024.
Who are the main investors in OnCusp?
Key investors in OnCusp include BioTrack Capital, F-Prime Capital, OrbiMed, Novo Holdings, HongShan.
Will OnCusp IPO soon?
No public IPO plans have been announced for OnCusp.
How can I track OnCusp secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OnCusp's secondary market activity and sign up for updates.